Project description
Early diagnosis of Alzheimer’s disease
Clinical practice employs immunoassay methods for the detection of diagnostic biomarkers in body fluids. However, in cases where the concentration of biomarkers falls below the limit of detection (LOD), these techniques fail to provide results. Alzheimer’s disease (AD) represents an example where low biomarker concentration in the blood makes diagnosis impossible. The EU-funded SensApp project is developing a super-sensitive technique to determine the concentration of AD biomarkers in plasma from peripheral blood samples for early non-invasive diagnosis in routine clinical practice. The so-called droplet split-and-stack technology will stack the biomarker molecules in sub-microlitre volumes on a solid support before immunodetection, avoiding diffusion and improving the LOD with an innovative integrated optical system detecting the fluorescence signal directly on the reaction support.
Fields of science
- medical and health scienceshealth sciencespublic health
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- humanitiesartsmodern and contemporary artcinematography
- engineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysis
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
00185 Roma
Italy
See on map
Participants (5)
1050 Brussel
See on map
98124 Messina
See on map
4040 Linz
See on map
02150 Espoo
See on map
90460 Oulunsalo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.